ORAMED PHARMACEUTICALS INC. (ORMP)
ORAMED PHARMACEUTICALS INC. (ORMP)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income (loss) | 38,310 | 10,009 | 48,389 | 5,618 |
| Depreciation | 30 | 30 | 31 | 60 |
| Exchange differences and interest on deposits | 140 | -80 | -823 | 73 |
| Changes in fair value of investments | 44,851 | -158,688 | 61,163 | 11,429 |
| Stock-based compensation | 1,736 | 2,284 | 719 | 2,989 |
| Gain on amounts funded in respect of employee rights upon retirement | 2 | 4 | 2 | 6 |
| Gain on sale of ip | 5,821 | NaN | NaN | NaN |
| Prepaid expenses and other current assets | -431 | 1,261 | 553 | -816 |
| Accounts payable, accrued expenses and related parties | 149 | 1,737 | 2,673 | -3,280 |
| Net changes in operating lease | 2 | 32 | 13 | 72 |
| Deferred revenue | -2,000 | 0 | 0 | -2,000 |
| Deferred income | 596 | -140 | 245 | NaN |
| Liability for employee rights upon retirement | 1 | 1 | 2 | 6 |
| Equity method investee | NaN | NaN | 0 | 250 |
| Deferred tax liabilities | -9,836 | 10 | -7,688 | -233 |
| Proceeds from long-term investments and marketable securities | NaN | 13,938 | 24,579 | 1,049 |
| Change in accrued interest on short-term borrowings | NaN | NaN | NaN | 0 |
| Other liabilities | 0 | 0 | 0 | -60 |
| Purchase of short-term deposits | NaN | 10,948 | NaN | 0 |
| Total net cash used in operating activities | -2,915 | -466 | -1,625 | -7,054 |
| Purchase of property and equipment | 5 | 2 | 0 | 7 |
| Purchase of marketable securities | 12,861 | 8,346 | 1,500 | NaN |
| Investments at fair value | -999 | -395 | -746 | -63,571 |
| Lifeward transactions | 11,924 | NaN | NaN | NaN |
| Equity method investee | NaN | 250 | NaN | NaN |
| Proceeds from investments | -1,077 | NaN | NaN | 4,599 |
| Purchase of convertible note | NaN | 3,000 | NaN | NaN |
| Proceeds from marketable securities | 2,779 | 2,865 | NaN | NaN |
| Advance payments for real estate | NaN | NaN | NaN | 1,949 |
| Proceeds from redemption of short-term deposits | 0 | 4,000 | 18,000 | 32,450 |
| Loan to investment in equity method | 0 | 0 | 0 | 7,000 |
| Proceeds from long-term deposits | NaN | NaN | NaN | 0 |
| Equity method investee | 0 | NaN | NaN | NaN |
| Proceeds from loan to an equity method investee | 0 | 0 | 2,809 | 3,442 |
| Real estate investment | 0 | -204 | 2,128 | NaN |
| Total net cash )used in) provided by investing activities | -19,488 | -1,684 | 38,364 | -31,237 |
| Loans repaid | NaN | NaN | NaN | 0 |
| Repurchase and retirement of common stock | NaN | 4,009 | 361 | 371 |
| Dividend paid | 10,364 | NaN | NaN | NaN |
| Total net cash used in financing activities | -10,364 | -4,009 | -361 | -371 |
| Effect of exchange rate changes on cash and cash equivalents | 22 | -73 | 4 | 39 |
| Increase (decrease) in cash and cash equivalents | -32,745 | -6,232 | 36,382 | -38,623 |
| Cash and cash equivalents at beginning of period | 45,947 | 52,179 | 54,420 | NaN |
| Cash and cash equivalents at end of period | 13,202 | 45,947 | 52,179 | NaN |